Drug Shortage Report for TEVA-NAPROXEN EC
Report ID | 109583 |
Drug Identification Number | 02243313 |
Brand name | TEVA-NAPROXEN EC |
Common or Proper name | NAPROXEN-EC 375MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | NAPROXEN |
Strength(s) | 375MG |
Dosage form(s) | TABLET (ENTERIC-COATED) |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | M01AE |
ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-03-25 |
Estimated end date | 2020-05-31 |
Actual end date | 2020-05-07 |
Shortage status | Resolved |
Updated date | 2020-05-08 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2020-05-08 | French | Compare |
v5 | 2020-05-08 | English | Compare |
v4 | 2020-04-09 | French | Compare |
v3 | 2020-04-09 | English | Compare |
v2 | 2020-03-26 | French | Compare |
v1 | 2020-03-26 | English | Compare |
Showing 1 to 6 of 6